Connection

Kathrin Jansen to Immunogenicity, Vaccine

Back to Details
This is a "connection" page, showing publications Kathrin Jansen has written about Immunogenicity, Vaccine.
Kathrin Jansen
Connection Strength
0.298
Immunogenicity, Vaccine
  1. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
    View in: PubMed
    Score: 0.074
  2. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med. 2021 07 29; 385(5):472-474.
    View in: PubMed
    Score: 0.074
  3. A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults. Vaccine. 2019 05 01; 37(19):2600-2607.
    View in: PubMed
    Score: 0.064
  4. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial. Vaccine. 2017 05 31; 35(24):3256-3263.
    View in: PubMed
    Score: 0.056
  5. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018 06; 17(6):461-477.
    View in: PubMed
    Score: 0.015
  6. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017 02 22; 35(8):1132-1139.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.